Formycon AG FYB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FYB is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- €47.80
- Day Range
- €45.85–48.40
- 52-Week Range
- €15.75–93.10
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €810.45 Mil
- Volume/Avg
- 0 / 9,809
Key Statistics
- Price/Earnings (Normalized)
- 8.16
- Price/Sales
- 9.48
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID-19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 162
- Website
- https://www.formycon.com
Comparables
Valuation
|
Metric
|
FYB
|
VCYT
|
XENE
|
|---|---|---|---|
Price/Earnings (Normalized) | 8.16 | 169.23 | — |
Price/Book Value | 1.47 | 1.43 | 3.17 |
Price/Sales | 9.48 | 4.09 | — |
Price/Cash Flow | 253.84 | 28.48 | — |
Price/Earnings
FYB
VCYT
XENE
Financial Strength
|
Metric
|
FYB
|
VCYT
|
XENE
|
|---|---|---|---|
Quick Ratio | 0.80 | 4.41 | 31.52 |
Current Ratio | 0.97 | 5.00 | 31.82 |
Interest Coverage | 954.16 | −11,324.57 | — |
Quick Ratio
FYB
VCYT
XENE
Profitability
|
Metric
|
FYB
|
VCYT
|
XENE
|
|---|---|---|---|
Return on Assets (Normalized) | −1.67% | 8.19% | −19.59% |
Return on Equity (Normalized) | −3.45% | 8.76% | −20.49% |
Return on Invested Capital (Normalized) | −3.86% | 7.87% | −24.56% |
Return on Assets
FYB
VCYT
XENE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Jtwtqpvt | Yfrnsw | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rbgqnbr | Yndlnm | $114.2 Bil | |||
| Moderna Inc
MRNA
| Cpwjqgnd | Xgt | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Vdrbljz | Yqpqc | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Rtgclgdk | Yfgf | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Cdlpynwz | Wlpbvyq | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lwxrngdr | Cldck | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Mqlxbqxsw | Nhjl | $12.8 Bil | |||
| Incyte Corp
INCY
| Pykyctgx | Rzgcxd | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Qjlwyzzdbk | Jpjtyk | $12.2 Bil |